Genflow Biosciences has signed a fully funded collaboration with Acuitas Therapeutics to test lipid nanoparticle delivery for its SIRT6-based gene therapy platform.
The deal gives Genflow access to Acuitas’ delivery technology without direct cost or shareholder dilution. Delivery is one of the main technical hurdles in gene therapy. A strong target is not enough, the therapy also needs an effective way to reach the right cells.
Under the agreement, Acuitas will formulate Genflow’s SIRT6 mRNA using its lipid nanoparticle technology. Genflow will then test the formulations in preclinical studies. The aim is to assess whether this delivery route can support the company’s broader work in age-related disease.
Genflow’s platform is built around a variant of the SIRT6 gene associated with exceptional human longevity. The company is developing gene therapies designed to address biological mechanisms linked to ageing and age-related conditions.
Because Acuitas is funding the work, Genflow can progress an important delivery experiment while conserving cash. If the preclinical work is successful, Genflow may gain stronger data around delivery, formulation and platform feasibility. That could help the company refine its development strategy and improve its position for future partnering discussions.
Genflow Biosciences plc (LON:GENF, OTCQB:GENFF, FRA:WQ5) is a UK-based biotech firm with R&D facilities in Belgium focused on developing novel therapeutic approaches that potentially halt or slow the aging process in humans and dogs supporting longer, healthier lives
